Advertisement

Einsatz von Antidepressiva und MAO-Hemmern in sequentieller Folge oder in Kombination miteinander als effiziente Strategie bei therapieresistenten Depressionen

  • M. Schmauss
  • A. Erfurth
  • M. Scholderle
Part of the Tropon-Symposium book series (BAYERZNS, volume 5)

Zusammenfassung

Hinsichtlich des Wirkmechanismus der Antidepressiva haben sich in den vergangenen Jahrzehnten zwei alternative Konzepte entwickelt, bei denen sich einerseits das Serotonin, andererseits das Noradrenalin im Mittelpunkt des Interesses befindet. Die häufig verordneten trizyklischen Antidepressiva hemmen in der Regel sowohl die Wiederaufnahme des Serotonins als auch des Noradrenalins, wobei die relative Intensität dieser beiden Wirkkomponenten jeweils unterschiedlich ist. Die Entwicklung neuerer Antidepressiva mit einer selektiven Beeinflussung der nora-drenergen und serotonergen Transmission hat einerseits Möglichkeiten eröffnet, den Einfluß monoaminerger Mechanismen bei der Pathogenese der Depression kritisch zu beleuchten und andererseits die therapeutischen Möglichkeiten in der Depressionsbehandlung erweitert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aberg-Wistedt A (1982) A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. I. Clinical findings. Acta Psychiat Scand 66:50–65PubMedCrossRefGoogle Scholar
  2. Ananth J, Luchins D (1977) A review of combined tricyclic and MAOI therapy. Compr Psychiatr 18:121–134CrossRefGoogle Scholar
  3. Ayd FJ jr (1975) Psychotropic drug combinations: good and bad. In: Greenblatt LDJ (ed) Drugs in combination with other therapies. Grune & Stratton, New York, pp 165–188Google Scholar
  4. Babiak J (1961) A case fatality of overdose of a combination of Parnate Tofranil. Can Med Assoc J 85:377–378PubMedGoogle Scholar
  5. Beaumont G (1973) Drug interactions with clomipramine (Anafranil). J Int Med Res 1:480–484Google Scholar
  6. Beckmann H (1981) Die medikamentöse Therapie der Depression. Nervenarzt 52:135–146PubMedGoogle Scholar
  7. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie, 4. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  8. Bowen LW (1964) Fatal hyperpyrexia with antidepressant drugs. Br Med J 2:1465PubMedCrossRefGoogle Scholar
  9. Caglieri-Cingolani R, Bencini A (1982) Due case mortali di reazione tossica per assoziazione di far- mace antidepressivi inhibitori delle mono-amino-ossidase e tricyclici. Riv Pat Nerv Ment 103:21–31Google Scholar
  10. Cohen SN, Armstrong MF (1974) Drug interactions: a handbook for clinical use. Williams & Wilkins, BaltimoreGoogle Scholar
  11. Davidson J, McLeod M, Law-Yone B, Linnoila M (1978) A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatr 35:639–642PubMedCrossRefGoogle Scholar
  12. Davies G (1960) Side effects of phenelzine. Br Med J 2:1019CrossRefGoogle Scholar
  13. d’Elia G, Hällström T, Nyström C, Ottosson J-O (1981) Zimelidine vs. maprotiline in depressed outpatients. A preliminary report. Acta Psychiatr Scand 63 [Suppl 290]: 225–235CrossRefGoogle Scholar
  14. Emrich HM, Berger M, v. Zerssen D (1986) Differential therapy of the depressive syndrome. In: Adv Pharmacother, vol 2. Karger, Basel, pp 57–64Google Scholar
  15. Gander DR (1967) The clinical value of monoamine oxidase inhibitors and tricyclic antidepressants in combination. In: Garattini S, Dukes MNG (eds) Antidepressant drugs. Excerpta Medica Foundation, AmsterdamGoogle Scholar
  16. Goldberg RS, Thornton WE (1978) Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. J Clin Pharmacol 18:143–147PubMedGoogle Scholar
  17. Graham PM, Potter JM, Patterson JW (1982) Combination monoamine oxidase inhibitor tricyclic antidepressant interaction. Lancet 11:440CrossRefGoogle Scholar
  18. Guilmot P, Rucquoy G (1967) Dangers in the too rapid substitution of imipramine for a monoamine oxidase inhibitor and in the combination of nialamine-isoniazid-barbiturates at high dosis in psychiatric therapy. Acta Neurol Belg 67:159–171Google Scholar
  19. Kelly D, Cuirgius W, Frommer E, Mitchell-Heggs N, Sargant W (1970) Treatment of phobic states with antidepressants. Br J Psychiatry 116:387–398PubMedCrossRefGoogle Scholar
  20. Kupfer DJ, Detre TP (1978) Tricyclic and monoamine oxidase inhibitor antidepressants - clinical use. In: Iversen L, Iversen S, Snyder S (eds) Handbook of Psychopharmacology 14. Plenum Press, New York London, pp 119–232Google Scholar
  21. Lee FI (1961) Imipramine overdosage-report of a fatal case. Br Med J 1:338–339PubMedCrossRefGoogle Scholar
  22. Lingjaerde O, Bratfos O, Bratlid T, Haug JO (1983) A double blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand 68:22–30PubMedCrossRefGoogle Scholar
  23. Loveless AH, Maxwell DR (1965) A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 25:158–170Google Scholar
  24. Marks J (1965) Interaction involving drugs used in psychiatry. In: Marks J, Pare CMB (eds) The Scientific Basis of Drug Therapy in Psychiatry. Pergamon Press, Oxford, pp 191–201Google Scholar
  25. Marley E, Wozniak KM (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychol Med 13:735–749PubMedCrossRefGoogle Scholar
  26. Murphy DL, Sunderland T, Cohen RM (1984) Monoamine oxidase-inhibiting antidepressants - a clinical update. Psychiatr Clin North Am 7:549–562PubMedGoogle Scholar
  27. Nolen W (1984) Effects of oxaprotiline, fluvoxamine, sleep deprivation, 5-HTP and tranylcypromine in resistant depression. Abstract, 14th CINP Congress, FlorenceGoogle Scholar
  28. Nieström C, Hällström T (1987) Comparison between a serotonin and noradrenaline reuptake blocker in the treatment of depressed outpatients. Acta Psychiatr Scand 75:377–382CrossRefGoogle Scholar
  29. Oefele K v., Grohmann R, Hippius H, Rüther E (1988) Unerwünschte Arzneimittelwirkungen bei der Kombinationsbehandlung mit trizyklischen Antidepressiva und Monoaminoxidase-Hemmern. Nervenarzt 59:118–123Google Scholar
  30. Pare CMB (1964) Toxicity of psychotropic drugs: side effects and toxic effects of antidepressants. Proc R Soc Med 57:757–778PubMedGoogle Scholar
  31. Pare CMB (1979) Monoamine oxidase inhibitors in resistant depression. Int Pharmacopsychiatr 14:101–109Google Scholar
  32. Pare CMB (1985) The present status of monoamine oxidase inhibitors. Br J Psychiatry 146:576–584PubMedCrossRefGoogle Scholar
  33. Peebles-Brown AE (1985) Hyperpyrexia following psychotropic drug overdose. Anaesthesia 40:1097–1099PubMedCrossRefGoogle Scholar
  34. Ponto LB, Perry PJ, Liskow BI, Scaba HH (1977) Drug therapy reviews: Tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 34:955–961Google Scholar
  35. Potter WZ, Calil HM, Extein I, Gold PW, Wehr TA, Goodwin FK (1981) Specific norepinephrine and serotonin uptake inhibitors in man: a crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters. Acta Psychiatr Scand [Suppl 290]: 152–165Google Scholar
  36. Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors: A review of antidepressant effectiveness. Arch Gen Psychiatry 36:749–760PubMedCrossRefGoogle Scholar
  37. Rafaelsen OJ, Gjerris A (1986) MAO-inhibitors revisited II: Clinical implications. In: Pichot P, Berner P, Wolf R, Thau K (eds) Psychiatry - The State of Art, vol II, pp 115–120Google Scholar
  38. Ray I (1973) Combinations of antidepressant drugs in the treatment of depressive illness. Can Psychiatr Assoc J 18:399–402PubMedGoogle Scholar
  39. Razani J, White K, White J, Simpson G, Sloane RB, Rebal R, Palmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Arch Gen Psychiatry 40:657–661PubMedCrossRefGoogle Scholar
  40. Sargant W, Walter CJS, Wright N (1966) New treatment of chronic tension states. Br Med J 1:322–324PubMedCrossRefGoogle Scholar
  41. Schmauß M, Erfurth A (1989) Indikationen für eine Therapie mit MAO-Hemmern. Psychiatr Praxis 16 [Suppl] :2–6Google Scholar
  42. Schmauß M, Meller I (1989) Die therapieresistente Depression - Ursachen und Behandlungsmöglichkeiten. Psychiatr Praxis 16:101–108Google Scholar
  43. Schmauß M, Kapfhammer HP, Meyr P, Hoff P (1988) Combined MAO-inhibitor and tri(tetra)cyclic antidepressant treatment in therapy resistant depression. Progr Neuro-Psychopharmacol Biol Psychiatr 12:523–532CrossRefGoogle Scholar
  44. Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 24:509–514PubMedCrossRefGoogle Scholar
  45. Sethna ER (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. Br J Psychiatry 124:265–272 (1974)PubMedCrossRefGoogle Scholar
  46. Sjoqvist F (1965) Psychotropic drugs II: interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med 58:967–978PubMedGoogle Scholar
  47. Spiker DG, Pugh DD (1976) Combining tricyclic and monoamine oxidase inhibitor antidepressants. Arch Gen Psychiatry 33:828–830PubMedCrossRefGoogle Scholar
  48. Stanley B, Pal WR (1964) Fatal hyperpyrecia with phenelzine and imipramine. Br Med J 2:1011PubMedCrossRefGoogle Scholar
  49. Teas GA (1981) Toxic delirium resulting from combination antidepressant therapy. Am J Psychiatry 138:1127PubMedGoogle Scholar
  50. Tollefson GD (1983) Monoamine oxidase inhibitors: a review. J Clin Psychiatry 44:280–288PubMedGoogle Scholar
  51. White K, Simpson G (1981) Combined MAOI-tricyclic antidepressant treatment. A reevaluation. J Clin Psychopharmacol 1:264–282PubMedCrossRefGoogle Scholar
  52. White K, Simpson G (1984) The combined use of MAOIs and Tricyclics. J Clin Psychiatry 45(2):67–69PubMedGoogle Scholar
  53. White K, Simpson G (1985) Should the use of MAO inhibitors be abandoned. Integr Psychiatry 3:34–45Google Scholar
  54. White K, Pistole TA, Boyd J (1980) Combined monoamine oxidase inhibitor tricyclic antidepressant treatment. A pilot study. Am J Psychiatry 137:1422–1425PubMedGoogle Scholar
  55. Winston F (1971) Combined antidepressant therapy. Br J Psychiatry 118:301–304PubMedCrossRefGoogle Scholar
  56. Young JPR, Lader MH, Hughes WC (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 2:1315–1317PubMedCrossRefGoogle Scholar
  57. Zisook S (1985) A clinical overview of monoamine oxidase inhibitors. Psychosomatics 26:240–251PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. Schmauss
  • A. Erfurth
  • M. Scholderle

There are no affiliations available

Personalised recommendations